This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tumor necrosis factor α -induced protein 8-like 3 (TNFAIP8L3; TIPE3); phosphoinositide 3-kinase (PI3K)	Studies in human samples and mice suggest inhibiting TNFAIP8L3 could help treat cancers that depend on oncogenic PI3K activity. In samples from patients with lung or esophageal cancer, TNFAIP8L3 levels were higher in tumor sections than in adjacent nontumor sections. In a carcinogen-induced mouse model of skin cancer, <i>Tnfaip8l3</i> knockout delayed skin tumor onset and decreased tumor size compared with no genetic alteration. Next steps include identifying a TNFAIP8L3-specific small molecule inhibitor.	Patent details available from the University of Pennsylvania; available for licensing	Fayngerts, S.A. <i>et al. Cancer Cell</i> ; published online Sept. 18, 2014; doi:10.1016/j.ccr.2014.07.025 Contact: Youhai H. Chen, University of Pennsylvania, Philadelphia, Pa. e-mail: yhc@mail.med.upenn.edu Contact: Yigong Shi, Tsinghua University, Beijing, China e-mail: ygshi@tsinghua.edu.cn
<i>SciBX</i> 7(39); doi:10.1038/scibx.2014.1148 Published online Oct. 9, 2014				